VJHemOnc is committed to improving our service to you

IACH Focus on Leukemia 2020 | Areas of further exploration in ALL

VJHemOnc is committed to improving our service to you

Christian Chabannon

Christian Chabannon, MD, PhD, Paoli-Calmettes Institute, Marseille, France, discusses the challenges in defining the relative importance of CAR T-cell therapy to other innovative therapies under development for acute lymphoblastic leukemia (ALL), such as bispecific antibodies. Further exploration is also needed to introduce the systematic use of minimal residual disease (MRD) to justify medical decisions. This interview took place during the 2020 Annual Meeting of the International Academy for Clinical Hematology (IACH).

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter